• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Graf Acquisition Corp. IV (Amendment)

    2/3/22 8:19:31 AM ET
    $GFOR
    Blank Checks
    Finance
    Get the next $GFOR alert in real time by email
    SC 13G/A 1 p22-0411sc13ga.htm GRAF ACQUISITION CORP. IV

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Graf Acquisition Corp. IV

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    384272100

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 38427210013G/APage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,124,431 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,124,431 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,124,431 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.24%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 38427210013G/APage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Graf Acquisition Corp. IV (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 1790 Hughes Landing Blvd., Suite 400, The Woodlands, Texas 77380.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Highbridge Funds.
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
     

    The address of the business office of Reporting Person is 277 Park Avenue, 23rd Floor,

    New York, New York 10172.

     

    Item 2(c). CITIZENSHIP:
       
      Highbridge is a Delaware limited liability company.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      384272100

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),

     

     

    CUSIP No. 38427210013G/APage 4 of 6 Pages

     

      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ___________________________________

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 21,452,875 shares of Common Stock reported to be outstanding as of November 15, 2021, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 15, 2021.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

     

    CUSIP No. 38427210013G/APage 5 of 6 Pages

     

    Item 10. CERTIFICATION.
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 38427210013G/APage 6 of 6 Pages

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 3, 2022

     

    HIGHBRIDGE CAPITAL MANAGEMENT, LLC
         
         
    By: /s/ Kirk Rule  
    Name: Kirk Rule  
    Title: Executive Director  
         

     

    Get the next $GFOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GFOR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GFOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Scott Kathleen D.

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    2/14/24 8:20:58 PM ET
    $GFOR
    Blank Checks
    Finance

    SEC Form 4 filed by Kim Yong Man

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    2/14/24 8:19:39 PM ET
    $GFOR
    Blank Checks
    Finance

    SEC Form 4 filed by Song Paul Y.

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    2/14/24 8:16:19 PM ET
    $GFOR
    Blank Checks
    Finance

    $GFOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Song Paul Y. bought $500 worth of shares (151 units at $3.30), increasing direct ownership by 0.09% to 171,121 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    12/7/23 5:23:12 PM ET
    $GFOR
    Blank Checks
    Finance

    Song Paul Y. bought $850 worth of shares (268 units at $3.17), increasing direct ownership by 0.16% to 170,969 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    12/5/23 3:51:22 PM ET
    $GFOR
    Blank Checks
    Finance

    Graf James A bought $2,172 worth of shares (670 units at $3.24), increasing direct ownership by 2,913% to 693 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    12/5/23 3:50:10 PM ET
    $GFOR
    Blank Checks
    Finance

    $GFOR
    SEC Filings

    View All

    Graf Acquisition Corp. IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - NKGen Biotech, Inc. (0001845459) (Filer)

    2/12/24 9:25:50 AM ET
    $GFOR
    Blank Checks
    Finance

    Graf Acquisition Corp. IV filed SEC Form 8-K: Leadership Update

    8-K - NKGen Biotech, Inc. (0001845459) (Filer)

    2/8/24 5:07:33 PM ET
    $GFOR
    Blank Checks
    Finance

    Graf Acquisition Corp. IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - NKGen Biotech, Inc. (0001845459) (Filer)

    1/22/24 6:12:43 AM ET
    $GFOR
    Blank Checks
    Finance

    $GFOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023

    THE WOODLANDS, Texas, Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 20, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 4:00 p.m., Eastern time, on September 25, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. The Company has decided to adjourn the Special M

    9/22/23 8:31:00 AM ET
    $GFOR
    Blank Checks
    Finance

    Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023

    THE WOODLANDS, Texas, Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 13, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 10:00 a.m., Eastern time, on September 20, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. As previously announced, the Company has recei

    9/14/23 9:00:00 AM ET
    $GFOR
    Blank Checks
    Finance

    Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023

    THE WOODLANDS, Texas, Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE:GFOR, GFOR.U, GFOR WS))) (the "Company" or "Graf"), announced today that on September 8, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting"). The Special Meeting will be reconvened at 4:00 p.m., Eastern time, on September 13, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023. As previously announced, the Company has receive

    9/11/23 11:08:00 AM ET
    $GFOR
    Blank Checks
    Finance

    $GFOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Graf Acquisition Corp. IV

    SC 13G - NKGen Biotech, Inc. (0001845459) (Subject)

    2/14/24 1:05:36 PM ET
    $GFOR
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Graf Acquisition Corp. IV (Amendment)

    SC 13G/A - NKGen Biotech, Inc. (0001845459) (Subject)

    2/14/24 6:28:12 AM ET
    $GFOR
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Graf Acquisition Corp. IV (Amendment)

    SC 13G/A - NKGen Biotech, Inc. (0001845459) (Subject)

    2/7/24 7:31:14 AM ET
    $GFOR
    Blank Checks
    Finance